News archive
Showing 680 results
May 2018
-
Media Release
Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
-
Media Release
Novartis and Amgen announce FDA approval of Aimovig™ (erenumab-aooe), a novel treatment developed specifically for migraine prevention
- Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States- Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-related… -
Media Release
Novartis and Amgen announce FDA approval of Aimovig™ (erenumab-aooe), a novel treatment developed specifically for migraine prevention
-
Media Release
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
- Results from the Kisqali® MONALEESA clinical trial program, the largest industry-sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will be… -
Media Release
Alcon teams up with Venus Williams, tennis champion and dry eye sufferer, to launch Systane® Complete eye drops
The new product joins the #1 doctor recommended Systane family of dry eye drops as the brand's most advanced solution to dateAlcon launches multimedia campaign to reach the 30 million people living… -
Media Release
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
-
Media Release
Alcon teams up with Venus Williams, tennis champion and dry eye sufferer, to launch Systane® Complete eye drops
-
Media Release
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
- New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)(1)- In a landmark… -
Media Release
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
-
Media Release
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response1Kymriah is the only CAR-T… -
Media Release
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
-
Media Release
Alcon Introduces AIR OPTIX® COLORS Contact Lenses Gemstone Collection, Creating New Ways to Enhance and Play with Eye Color